StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their target price on Trevena from $225.00 to $125.00 and set a “buy” rating for the company in a research report on Thursday, May 16th.

Trevena Stock Down 2.4 %

Shares of Trevena stock opened at $4.46 on Tuesday. The business has a 50 day moving average of $5.67 and a 200 day moving average of $9.56. Trevena has a 52 week low of $3.35 and a 52 week high of $28.00. The company has a market cap of $3.79 million, a PE ratio of -1.66 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million during the quarter. On average, research analysts anticipate that Trevena will post -32.25 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent reporting period. Institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.